Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacill... von Boormans, J.L., De Wit, R., Kulkarni, G.S., Uchio, E.M., Roumiguié, M., Krieger, L.E.M., Singer, E.A., Bajorin, D.F., Kamat, A.M., Grivas, P., Seo, H.K., Nishiyama, H., Konethy, B.R., Saretsky, T., Li, H., Nam, K., Kapadia, E., Balar, A.V.

Volltext

81 The presentation and management of thymic epithelial malignancies & the Guy's and St Thomas' hospital experience von Krieger, L.E.M, Lal, R, Lang-Lazdunski, L, Harrison-Phipps, K, Chowdhury, F

Volltext

1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601) von Gedye, C., Harris, C.A., Stockler, M.R., Morris, M., Ferguson, T., Goh, J.C.H., Martin, A., Underhill, C.R., Pook, D., Krieger, L.E.M., Kichenadasse, G., Joshi, A.J., Subramaniam, S., Zebic, D.S., Zhang, A., Joshua, A.M., Toner, G.C., Vasey, P.A., Prithviraj, P., Davis, I.D.

Volltext

916P - Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle inv... von de Wit, R., Kulkarni, G.S., Uchio, E., Boormans, J.L., Roumiguié, M., Krieger, L.E.M., Singer, E.A., Bajorin, D.F., Kamat, A.M., Grivas, P., Seo, H.K., Nishiyama, H., Konety, B.R., Saretsky, T., Li, H., Nam, K., Sbar, E., Balar, A.V.

Volltext

Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive b... von de Wit, R., Kulkarni, G.S., Uchio, E., Boormans, J.L., Roumiguié, M., Krieger, L.E.M., Singer, E.A., Bajorin, D.F., Kamat, A.M., Grivas, P., Seo, H.K., Nishiyama, H., Konety, B.R., Saretsky, T., Li, H., Nam, K., Sbar, E., Balar, A.V.

Volltext